BRPI0109494B8 - muteína de fator viii, sequência de dna, vetor, processo para produção da muteína de fator viii, composição farmacêutica e uso da muteína do fator viii - Google Patents
muteína de fator viii, sequência de dna, vetor, processo para produção da muteína de fator viii, composição farmacêutica e uso da muteína do fator viiiInfo
- Publication number
- BRPI0109494B8 BRPI0109494B8 BRPI0109494A BR0109494A BRPI0109494B8 BR PI0109494 B8 BRPI0109494 B8 BR PI0109494B8 BR PI0109494 A BRPI0109494 A BR PI0109494A BR 0109494 A BR0109494 A BR 0109494A BR PI0109494 B8 BRPI0109494 B8 BR PI0109494B8
- Authority
- BR
- Brazil
- Prior art keywords
- factor viii
- viii mutein
- vector
- dna sequence
- factor
- Prior art date
Links
- 229960000301 factor viii Drugs 0.000 title abstract 7
- 108091028043 Nucleic acid sequence Proteins 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000003114 blood coagulation factor Substances 0.000 abstract 3
- 210000005260 human cell Anatomy 0.000 abstract 3
- 238000004519 manufacturing process Methods 0.000 abstract 3
- 230000003213 activating effect Effects 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 230000006490 viral transcription Effects 0.000 abstract 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 abstract 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 abstract 1
- 208000031220 Hemophilia Diseases 0.000 abstract 1
- 208000009292 Hemophilia A Diseases 0.000 abstract 1
- 229940019700 blood coagulation factors Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229960004222 factor ix Drugs 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
produção de fatores recombinantes de coagulação do sangue em linhas celulares humanas. a presente invenção refere-se a um processo melhorado para a produção de fatores recombinantes de coagulação do sangue humano, em particular do fator viii e fator ix, utilizando uma linhagem celular humana imortalizada expressando estavelmente proteínas ativadoras de transcrição viral e carregando um vetor tendo um promotor funcionalmente ligado a uma seqüência de dna codificando para um fator de coagulação do sangue, desde que o dito promotor não seja um promotor viral que seja estimulado pelas ditas proteínas ativadoras de transcrição viral; e linhagem celular humana imortalizada carregando o dito vetor; muteínas do fator viii particularmente adequadas para o processo de produção acima; composições farmacêuticas compreendendo tais muteínas do fator viii e a utilização de tais muteínas do fator viii para a preparação de um medicamento para o tratamento de hemofilia.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00106225.6 | 2000-03-22 | ||
| EP00106225A EP1136553A1 (en) | 2000-03-22 | 2000-03-22 | Production of recombinant blood clotting factors in human cell lines |
| US20324900P | 2000-05-08 | 2000-05-08 | |
| US60/203,249 | 2000-05-08 | ||
| PCT/EP2001/003220 WO2001070968A2 (en) | 2000-03-22 | 2001-03-21 | Production of recombinant blood clotting factors in human cell lines |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR0109494A BR0109494A (pt) | 2002-12-10 |
| BRPI0109494B1 BRPI0109494B1 (pt) | 2021-05-11 |
| BRPI0109494B8 true BRPI0109494B8 (pt) | 2021-05-25 |
Family
ID=26070708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0109494A BRPI0109494B8 (pt) | 2000-03-22 | 2001-03-21 | muteína de fator viii, sequência de dna, vetor, processo para produção da muteína de fator viii, composição farmacêutica e uso da muteína do fator viii |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US7572619B2 (pt) |
| EP (2) | EP1460131A3 (pt) |
| JP (1) | JP3894795B2 (pt) |
| KR (1) | KR100581574B1 (pt) |
| CN (1) | CN1454257B (pt) |
| AT (1) | ATE312176T1 (pt) |
| AU (3) | AU5471501A (pt) |
| BE (1) | BE2014C077I2 (pt) |
| BG (1) | BG65930B1 (pt) |
| BR (1) | BRPI0109494B8 (pt) |
| CA (1) | CA2404163C (pt) |
| CZ (1) | CZ303929B6 (pt) |
| DE (1) | DE60115613T2 (pt) |
| DK (1) | DK1266006T3 (pt) |
| EA (1) | EA004317B1 (pt) |
| EE (1) | EE200200538A (pt) |
| ES (1) | ES2254403T3 (pt) |
| FR (1) | FR15C0003I2 (pt) |
| HR (1) | HRP20020767B1 (pt) |
| HU (1) | HU228091B1 (pt) |
| IL (2) | IL151857A0 (pt) |
| MX (1) | MXPA02009221A (pt) |
| NO (1) | NO330910B1 (pt) |
| NZ (1) | NZ521732A (pt) |
| RS (1) | RS50743B (pt) |
| SI (1) | SI1266006T1 (pt) |
| SK (1) | SK287706B6 (pt) |
| WO (1) | WO2001070968A2 (pt) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL151857A0 (en) * | 2000-03-22 | 2003-04-10 | Octagene Gmbh | Production of recombinant blood clotting factors in human cell lines |
| HUP0301179A3 (en) * | 2000-09-19 | 2006-11-28 | Univ Emory | Modified factor viii |
| EP1469064A1 (en) | 2003-04-15 | 2004-10-20 | DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH | Expression of proteins in endothelial cells derived from precursor cells from cord blood |
| ATE489105T1 (de) * | 2004-03-19 | 2010-12-15 | Baxter Int | Faktor ixa zur behandlung von blutungsstörungen |
| KR100624013B1 (ko) * | 2004-06-25 | 2006-09-19 | 주식회사 녹십자홀딩스 | 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제 |
| ATE549037T1 (de) | 2004-09-22 | 2012-03-15 | St Jude Childrens Res Hospital | Verbesserte expression von faktor-ix in gentherapie-vektoren |
| US20060094104A1 (en) | 2004-10-29 | 2006-05-04 | Leopold Grillberger | Animal protein-free media for cultivation of cells |
| US8530192B2 (en) * | 2005-02-11 | 2013-09-10 | Novo Nordisk Healthcare Ag | Production of a polypeptide in a serum-free cell culture liquid containing plant protein hydrolysate |
| EP1707634A1 (en) | 2005-03-29 | 2006-10-04 | Octapharma AG | Method for isolation of recombinantly produced proteins |
| EP1739179A1 (en) | 2005-06-30 | 2007-01-03 | Octapharma AG | Serum-free stable transfection and production of recombinant human proteins in human cell lines |
| KR101495549B1 (ko) | 2006-07-13 | 2015-02-25 | 와이어쓰 엘엘씨 | 당단백질의 생산 |
| CA3090908A1 (en) * | 2007-04-26 | 2008-11-06 | Aptevo Biotherapeutics Llc | Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same |
| JPWO2009028575A1 (ja) * | 2007-08-27 | 2010-12-02 | 国立大学法人名古屋大学 | 血液凝固第ｖｉｉ因子プロモーターの活性化剤及びその利用 |
| MX2011001624A (es) | 2008-08-21 | 2011-03-28 | Octapharma Ag | Factor viii y ix humano producido en forma recombinante. |
| WO2010092135A2 (en) | 2009-02-11 | 2010-08-19 | Novozymes Biopharma Uk Ltd. | Albumin variants and conjugates |
| ES2717902T5 (es) | 2009-10-02 | 2022-11-29 | Childrens Hospital Philadelphia | Composiciones y procedimientos para mejorar la función del factor VIII de coagulación |
| BR112012009450A2 (pt) | 2009-10-30 | 2017-05-23 | Novozymes Biopharma Dk As | variantes de albumina |
| EP2556087A1 (en) | 2010-04-09 | 2013-02-13 | Novozymes Biopharma DK A/S | Albumin derivatives and variants |
| BRPI1105317A2 (pt) | 2011-01-24 | 2013-04-30 | Fundacco Hemoct De Ribeirco Preto | produÇço estÁvel e em larga escala de fviii humano em linhagem celular humana sk-hep-1 |
| CA2827923C (en) | 2011-02-25 | 2021-11-23 | Chugai Seiyaku Kabushiki Kaisha | Fc.gamma.riib-specific fc antibody |
| CN102199607B (zh) * | 2011-03-30 | 2012-11-14 | 山西大学 | 重组人凝血因子ix小基因及其ptc突变体稳定细胞株 |
| WO2012156356A1 (en) | 2011-05-13 | 2012-11-22 | Octapharma Ag | A method of increasing the productivity of eucaryotic cells in the production of recombinant fviii |
| TW201307563A (zh) * | 2011-05-19 | 2013-02-16 | Shire Human Genetic Therapies | 純化乙醯肝素－ｎ－硫酸酯酶之方法 |
| CN102321668A (zh) * | 2011-07-06 | 2012-01-18 | 中国人民解放军军事医学科学院野战输血研究所 | 一种表达重组人凝血因子ⅶ的方法及其专用载体 |
| EP3939996A1 (en) | 2011-09-30 | 2022-01-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
| KR20140084208A (ko) | 2011-10-18 | 2014-07-04 | 시에스엘 리미티드 | 정제된 인자 ｖｉｉｉ의 재구성 후의 안정성을 향상시키는 방법 |
| WO2013075066A2 (en) | 2011-11-18 | 2013-05-23 | Eleven Biotherapeutics, Inc. | Proteins with improved half-life and other properties |
| BR112014013081A2 (pt) | 2011-11-30 | 2020-10-20 | Chugai Seiyaku Kabushiki Kaisha | veículo contendo fármaco em célula para formação de um complexo imune |
| EP2825556B1 (en) | 2012-03-16 | 2018-01-03 | Albumedix A/S | Albumin variants |
| US9550819B2 (en) | 2012-03-27 | 2017-01-24 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| GB201210357D0 (en) | 2012-06-12 | 2012-07-25 | Ucl Business Plc | Factor VIII sequences |
| US8986991B2 (en) * | 2012-07-03 | 2015-03-24 | Expression Therapeutics, Llc | High yield suspension cell line, system and method for making same |
| US10023628B2 (en) | 2012-07-06 | 2018-07-17 | Bioverativ Therapeutics Inc. | Cell line expressing single chain factor VIII polypeptides and uses thereof |
| KR20150082422A (ko) | 2012-11-08 | 2015-07-15 | 노보자임스 바이오파마 디케이 에이/에스 | 알부민 변이체 |
| CA2898975C (en) * | 2013-01-24 | 2021-06-15 | Portola Pharmaceuticals, Inc. | Inhibition of tissue factor pathway inhibitor with factor xa derivatives |
| CN113621057A (zh) | 2013-04-02 | 2021-11-09 | 中外制药株式会社 | Fc区变体 |
| EP2853538A1 (en) | 2013-09-27 | 2015-04-01 | Université Pierre et Marie Curie (Paris 6) | Analogues of temporin-SHa and uses thereof |
| EA035581B1 (ru) * | 2014-07-30 | 2020-07-10 | НДжМ БИОФАРМАСЬЮТИКАЛЗ, ИНК. | Композиции и способы применения для лечения метаболических расстройств |
| PL3212226T3 (pl) | 2014-10-31 | 2020-11-02 | Ngm Biopharmaceuticals, Inc. | Kompozycje i sposoby stosowania w leczeniu zaburzeń metabolicznych |
| GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
| AR103161A1 (es) | 2014-12-19 | 2017-04-19 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso |
| BR102015012334A2 (pt) | 2015-05-27 | 2016-11-29 | Fundação Hemoct De Ribeirão Preto Fundherp | processo de produção do fator vii de coagulação sanguínea e fator vii de coagulação sanguínea |
| WO2016198499A1 (en) | 2015-06-09 | 2016-12-15 | Glycotope Gmbh | IMPROVED METHOD FOR PRODUCTION OF γ-CARBOXYLATED POLYPEPTIDES |
| CA2989966C (en) | 2015-08-20 | 2024-04-30 | Albumedix A/S | Albumin variants and conjugates |
| CN105219739A (zh) * | 2015-09-21 | 2016-01-06 | 北京神源德生物科技有限公司 | 重组单纯疱疹病毒及它感染和制备它的宿主细胞以及它们的应用 |
| EP3394098A4 (en) | 2015-12-25 | 2019-11-13 | Chugai Seiyaku Kabushiki Kaisha | ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE |
| CN109562191A (zh) | 2016-04-15 | 2019-04-02 | 宾夕法尼亚州大学信托人 | 用于治疗血友病a的基因疗法 |
| CA3026050A1 (en) | 2016-08-05 | 2018-02-08 | Chugai Seiyaku Kabushiki Kaisha | Composition for prophylaxis or treatment of il-8 related diseases |
| WO2018210771A1 (en) | 2017-05-17 | 2018-11-22 | Octapharma Ag | Method for the production of a recombinant target protein |
| US12084513B2 (en) | 2017-11-14 | 2024-09-10 | Chugai Seiyaku Kabushiki Kaisha | Anti-C1S antibodies and methods of use |
| WO2020020364A1 (zh) * | 2018-07-26 | 2020-01-30 | 正大天晴药业集团南京顺欣制药有限公司 | 一种制备重组人凝血因子ⅷ的方法 |
| WO2020032230A1 (ja) | 2018-08-10 | 2020-02-13 | 中外製薬株式会社 | 抗ｃｄ１３７抗原結合分子およびその使用 |
| GB201813528D0 (en) | 2018-08-20 | 2018-10-03 | Ucl Business Plc | Factor IX encoding nucleotides |
| US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
| CN113301911B (zh) | 2018-10-23 | 2025-07-15 | 费城儿童医院 | 用于调节因子viii功能的组合物和方法 |
| CA3221235A1 (en) | 2021-06-11 | 2022-12-15 | Ali Ladram | Short antimicrobial peptides |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL74909A (en) * | 1984-04-20 | 1992-01-15 | Genentech Inc | Preparation of functional human factor viii and dna sequences,expression vectors,transformed microorganisms and cell lines used therein |
| JPS6171774A (ja) * | 1984-09-14 | 1986-04-12 | Sony Corp | テレビジヨンカメラ装置のビ−ム電流制御装置 |
| US4770999A (en) * | 1985-04-22 | 1988-09-13 | Genetics Institute, Inc. | High yield production of active Factor IX |
| EP0253870B1 (en) * | 1986-01-03 | 1993-03-31 | Genetics Institute, Inc. | Method for producing factor viii:c-type proteins |
| US5422260A (en) | 1986-05-29 | 1995-06-06 | Genetics Institute, Inc. -Legal Affairs | Human factor VIII:c muteins |
| US5451521A (en) * | 1986-05-29 | 1995-09-19 | Genetics Institute, Inc. | Procoagulant proteins |
| US5024939A (en) | 1987-07-09 | 1991-06-18 | Genentech, Inc. | Transient expression system for producing recombinant protein |
| FR2638643B1 (fr) * | 1988-11-09 | 1991-04-12 | Transgene Sa | Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants |
| KR927003812A (ko) * | 1989-11-17 | 1992-12-18 | 노보 노르디스크 아크티에 셀스카브 | 인자 viii:c 활성을 갖는 단백질 복합체 및 그의 제조 |
| SE465222C5 (sv) * | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
| ATE103982T1 (de) * | 1990-01-26 | 1994-04-15 | Immuno Ag | Rekombinant hergestellte blutfaktoren, verfahren zur exprimierung besagter blutfaktoren sowie in besagtem prozess verwendeter rekombinanter vaccina-virus. |
| US5445953A (en) * | 1991-08-26 | 1995-08-29 | Immuno Aktiengesellschaft | Direct molecular cloning of a modified poxvirus genome |
| CA2162497A1 (en) * | 1993-06-10 | 1994-12-22 | Sheila Connelly | Adenoviral vectors for treatment of hemophilia |
| WO1998000541A2 (en) * | 1996-07-03 | 1998-01-08 | Chiron Corporation | Methods for administration of recombinant gene delivery vehicles for treatment of human disease |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| CA2312291A1 (en) * | 1997-12-05 | 1999-06-17 | The Immune Response Corporation | Novel vectors and genes exhibiting increased expression |
| US6358703B1 (en) * | 1998-12-10 | 2002-03-19 | Bayer Corporation | Expression system for factor VIII |
| EP1151099A1 (en) * | 1999-02-19 | 2001-11-07 | Octagene GmbH | Hormone-hormone receptor complexes and nucleic acid constructs and their use in gene therapy |
| AU6770200A (en) * | 1999-08-13 | 2001-03-13 | Fred Hutchinson Cancer Research Center | Crystal of a truncated protein construct containing a coagulation factor viii c2domain in the presence or absence of a bound ligand and methods of use thereof |
| IL151857A0 (en) * | 2000-03-22 | 2003-04-10 | Octagene Gmbh | Production of recombinant blood clotting factors in human cell lines |
| WO2003009237A1 (en) * | 2001-07-18 | 2003-01-30 | Skaginn Hf. | A method and apparatus for relating information of a processed object to an operator |
-
2001
- 2001-03-21 IL IL15185701A patent/IL151857A0/xx unknown
- 2001-03-21 HR HR20020767A patent/HRP20020767B1/xx not_active IP Right Cessation
- 2001-03-21 ES ES01927769T patent/ES2254403T3/es not_active Expired - Lifetime
- 2001-03-21 DE DE60115613T patent/DE60115613T2/de not_active Expired - Lifetime
- 2001-03-21 EA EA200201008A patent/EA004317B1/ru active Protection Beyond IP Right Term
- 2001-03-21 SI SI200130501T patent/SI1266006T1/sl unknown
- 2001-03-21 KR KR1020027012443A patent/KR100581574B1/ko not_active Expired - Lifetime
- 2001-03-21 AT AT01927769T patent/ATE312176T1/de active
- 2001-03-21 CA CA002404163A patent/CA2404163C/en not_active Expired - Lifetime
- 2001-03-21 BR BRPI0109494A patent/BRPI0109494B8/pt not_active IP Right Cessation
- 2001-03-21 SK SK1504-2002A patent/SK287706B6/sk not_active IP Right Cessation
- 2001-03-21 EE EEP200200538A patent/EE200200538A/xx unknown
- 2001-03-21 WO PCT/EP2001/003220 patent/WO2001070968A2/en active IP Right Grant
- 2001-03-21 RS YUP-710/02A patent/RS50743B/sr unknown
- 2001-03-21 NZ NZ521732A patent/NZ521732A/en not_active IP Right Cessation
- 2001-03-21 DK DK01927769T patent/DK1266006T3/da active
- 2001-03-21 MX MXPA02009221A patent/MXPA02009221A/es active IP Right Grant
- 2001-03-21 CN CN018097456A patent/CN1454257B/zh not_active Expired - Lifetime
- 2001-03-21 AU AU5471501A patent/AU5471501A/xx active Pending
- 2001-03-21 EP EP04009279A patent/EP1460131A3/en not_active Withdrawn
- 2001-03-21 US US10/239,498 patent/US7572619B2/en not_active Expired - Lifetime
- 2001-03-21 AU AU2001254715A patent/AU2001254715B2/en not_active Expired
- 2001-03-21 HU HU0300588A patent/HU228091B1/hu unknown
- 2001-03-21 JP JP2001569351A patent/JP3894795B2/ja not_active Expired - Lifetime
- 2001-03-21 EP EP01927769A patent/EP1266006B1/en not_active Expired - Lifetime
- 2001-03-21 CZ CZ20023166A patent/CZ303929B6/cs not_active IP Right Cessation
-
2002
- 2002-09-19 NO NO20024475A patent/NO330910B1/no not_active IP Right Cessation
- 2002-09-19 IL IL151857A patent/IL151857A/en active IP Right Grant
- 2002-09-26 BG BG107152A patent/BG65930B1/bg unknown
-
2006
- 2006-05-02 AU AU2006201848A patent/AU2006201848A1/en not_active Abandoned
-
2014
- 2014-12-29 BE BE2014C077C patent/BE2014C077I2/fr unknown
-
2015
- 2015-01-20 FR FR15C0003C patent/FR15C0003I2/fr active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0109494B8 (pt) | muteína de fator viii, sequência de dna, vetor, processo para produção da muteína de fator viii, composição farmacêutica e uso da muteína do fator viii | |
| Shoyab et al. | Structure and function of human amphiregulin: a member of the epidermal growth factor family | |
| DE68917300T2 (de) | Heilung von wunden. | |
| ATE182901T1 (de) | Für androgen-rezeptor-protein kodierende dna | |
| ES2094111T3 (es) | Proteinas con actividad de factor viii, procedimiento para su produccion que utilizan celulas modificadas por ingenieria genetica y composiciones farmaceuticas que las contienen. | |
| ATE467425T1 (de) | Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben | |
| BR0309877A (pt) | Peptìdeos estimuladores de tecido conectivo | |
| BR9608019A (pt) | Uma nova proteína e um processo para a preparação da mesma' | |
| ATE265529T1 (de) | Bmp-10 zusammensetzungen | |
| CY1112655T1 (el) | Γλυκοζυλιωμενη ιl-7, παρασκευη και χρησεις | |
| DK0861261T3 (da) | Nukleotid- og proteinsekvenser af hvirveldyrs-Delta-gener og fremgangsmåder baseret derpå | |
| BR0009074A (pt) | Proteìna para bloquear adesão de plaqueta | |
| PT93082A (pt) | Processo de producao de um derivado de activador de plaminogenio tissular, de plasmideo de expressao e de medicamento contendo o referido derivado | |
| BR112022011975A2 (pt) | Polipeptídeo de interferon-¿2 modificado, polipeptídeo gmop-interferon-¿2 modificado, ácido nucleico, plasmídeo, vetor, linha de célula, método para purificação do polipeptídeo de interferon-¿2 modificado, composição farmacêutica, método para uso de um ou mais dos polipeptídeos de interferon-¿2 modificados e método para tratar uma condição médica em um indivíduo | |
| ATE294236T1 (de) | Promotor der tie rezeptor protein kinase | |
| AR037038A1 (es) | Una composicion y metodo para alterar la masa corporal magra y las propiedades oseas en un sujeto | |
| EA021186B1 (ru) | Композиции, включающие интерлейкин-1 и пептиды | |
| NZ508505A (en) | Treatment of wounds using an Egr-1 transcription factor polypeptide | |
| DE69227921D1 (de) | Herstellung von Proteinen mittels Protein 7B2 | |
| ATE111525T1 (de) | Plasminogenaktivator-varianten und verfahren zu ihrer herstellung. | |
| KR890006815A (ko) | 산성 섬유아세포 생장인자의 돌연변이체 | |
| BR9908096A (pt) | Proteìna 3 da zona pelúcida humana (hzp3), ativa, recombinante | |
| PT704527E (pt) | Sequencias de adn que codificam precursores de insulina biossinteticos e processo para a preparacao de insulina | |
| Lin et al. | Granule proteins of the dental follicle and stellate reticulum inhibit tooth eruption and eyelid opening in postnatal rats | |
| CN100334114C (zh) | 一种新型融合蛋白及其制备 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25G | Requested change of headquarter approved |
Owner name: OCTAGENE GMBH (DE) Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020060052755/RJ DE 17/04/2006. |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25D | Requested change of name of applicant approved |
Owner name: OCTAPHARMA BIOPHARMACEUTICALS GMBH (DE) Free format text: NOME ALTERADO DE: OCTAGENE GMBH |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: OCTAPHARMA AG (CH) |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/03/2001, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/03/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 21/03/2021 |